When was Protembis founded?

Protembis was founded in 2013 and raised its 1st funding round 2 years after it was founded.

Where is Protembis located?

Protembis is headquartered in Aachen, Germany. It is registered at Aachen.

Which legal entities is Protembis associated with?

Protembis is associated with Protembis Gmbh.

How many employees does Protembis have?

As of May 31, 2026, the latest employee count at Protembis is 19.

Is Protembis a funded company?

Protembis is a funded company, having raised a total of $45.2M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 24, 2015.

When was the latest funding round of Protembis?

Protembis' latest funding was a $***** Venture Debt round on Jul 30, 2024, with participation from 1 investor.

Where does Protembis rank among its competitors?

Protembis ranks 4th amongst 16 active competitors, of which 7 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Emboline, which secured $20M in Mar, 2026.

Who are the top competitors of Protembis?

Protembis' top competitors include Synaptive Medical, Emboline and Claret Medical. Among them, Emboline secured the most recent funding round in March, 2026.

Protembis - 2026 Company Profile, Team, Funding, Competitors & Financials

Protembis is a public company based in Aachen (Germany), founded in 2013 by Conrad Rasmus. It operates as a Manufacturer of cerebral protection device. Protembis has raised $45.2M in funding from investors like Abiomed, Geratherm Medical AG and IFB Innovationsstarter. The company has 16 active competitors, including 7 funded and 5 that have exited. Its top competitors include companies like Synaptive Medical, Emboline and Claret Medical.

Company Details

Manufacturer of cerebral protection device It produces a cerebral protection device for use during cardiac surgeries involving the left heart to prevent strokes. Their device consists of an implantable filter system that can be introduced into the aortic arch during minimally invasive procedures which prevent the migration of embolic particles into the cerebral vasculature which prevents strokes.

Website: protembis.com
Email ID: *****@protembis.com
Phone Number: +49 **********
Registered Address: Aachen

Key Metrics

Founded Year

2013

Location

Aachen, Germany

Stage

Public

Total Funding

$45.2M in 5 rounds

Latest Funding Round

Venture Debt, Jul 30, 2024, $*****

Investors

Abiomed & 20 more

Ranked

4^th among 16 active competitors

Employee Count

19 as on May 31, 2026

Similar Companies

Synaptive Medical & 19 more

Exit Details

Public

View Protembis' full profile

Protembis is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Protembis Gmbh CIN: HRB21218 , Germany, Active	May 21, 2017	-	3 (As on Dec 31, 2018)

Protembis has raised a total funding of $45.2M over 5 rounds. Its first funding round was on Apr 24, 2015. Its latest funding round was a Venture Debt round on Jul 30, 2024 for $*****. 1 investor participated in its latest round. Protembis has 15 institutional investors and 6 angel investors.

Here is the list of recent funding rounds of Protembis:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 30, 2024	4223273	Venture Debt	4614896	7936775	5760921	3624130
Mar 26, 2024	3572953	Series B	7957688	9742992	3068790	TechVision Fonds
Oct 25, 2018	8210551	Series A	1164436	9927861	Abiomed & 1 more	TechVision Fonds

Access funding benchmarks and valuations. Sign up today!

View details of Protembis's funding rounds and investors

The founders of Protembis is Conrad Rasmus.

Here are the details of Protembis' key team members:

Conrad Rasmus: Co-Founder & Co-CEO of Protembis.

View details of Protembis's Founder profiles and Board Members

Protembis' employee count trend

Protembis has 19 employees as of May 26. Here is Protembis's employee count trend over the years:

Uncover Protembis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Protembis include Synaptive Medical, Emboline and Claret Medical. Here is the list of Top 10 competitors of Protembis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synaptive Medical 2012, Mississauga (Canada), Series C	Planning and imaging solutions for neurosurgery	$76.8M	General Atlantic, Sensegain Capital & 10 others	63/100
2nd	Emboline 2011, Santa Cruz (United States), Series D	Developer of an aortic embolic protection device	$102M	SV Tech Ventures, Matrix Capital Management ... & 9 others	57/100
3rd	Claret Medical 2009, Santa Rosa (United States), Acquired	Developer of cerebral vascular protection systems for use during endovascular procedures	$51.4M	Sante Ventures, Lightstone Ventures & 6 others	53/100
4th	Protembis 2013, Aachen (Germany), Public	Manufacturer of cerebral protection device	$45.2M	Coparion, European Investment Bank & 19 others	47/100
5th	Filterlex Medical 2015, Tel Aviv (Israel), Series B	Developer of an embolic protection device	$16.9M	Medical Technology Venture Partners, Europa ... & 3 others	46/100
6th	Transverse Medical 2011, Golden (United States), Series B	Developer of a device to prevent stroke during transcatheter aortic valve replacement heart procedures	$26.8M	Grant Park Ventures, Flight Partners Capital	40/100
7th	NeuraMedica 2014, Oregon City (United States), Seed	Developer of a dural clip that helps in durotomy and orthopedic spinal closures	$1.85M	NIH, ONAMI & 1 others	35/100
8th	Invictus Medical 2010, San Antonio (United States), Series A	Innovating NICU environments, improving newborn lives through noise reduction technology	$8.93M	-	35/100
9th	Keystone Heart 2004, Tampa (United States), Acquired	Embolic cerebral protection devices	$14M	Western Technology Investment, Orbimed	32/100
10th	Embrella Cardiovascular 2007, Malvern (United States), Acquired	Cardiovascular procedure protection	$6.7M	BioStar Capital, Edwards Lifesciences & 2 others	32/100